Medgenics(Regs) Share Discussion Threads

[sicilian_kan] 07/6/2010 17:40

True, well it was the only rational reason I could think of. Interesting that MEDU's share price held up near 20p despite the RNS at the end of lunch.

[ihavenoclue] 07/6/2010 14:11

Nope no deal news ...

[sicilian_kan] 07/6/2010 13:31

This looks like the sort of rise you get on deal news. Anyone wanting to buy a big stake could have done so in the recent fundraisings. I can't think what else could explain it. Perhaps the company will be forced to issue an RNS.

[sicilian_kan] 07/6/2010 13:30

Another tick up for MEDU.

[sicilian_kan] 07/6/2010 13:21

arnie, on the MEDU thread they state Red Hot Penny Shares, but the MEDU buying has gone on for a few weeks now. It doesn't tally from my point of view. There was also a conversion of warrants into shares by Andrew Pearlman's wife today. But that also doesn't explain the rise in MEDU which shot up from 10p to 35p before settling at 23.5p at the moment. MEDG, at 8.25p, has a long way to go to catch up its sister share MEDU. Either this will go up or MEDU will come back down, or it could be both.

[tez123] 07/6/2010 10:54

Thanks for your prompt response KAN,

Kind Regards

Tez

[arnie72] 07/6/2010 09:51

Any reason for the jump this morning???

[sicilian_kan] 06/6/2010 20:16

tez123,

Both tickers are of the same nominal value, so if holding for a takeover / dividend etc. then there is no difference. This can be seen by the fact that MEDU is now much more expensive than MEDG, whilst a few weeks ago, MEDG was much more expensive than MEDU. It really depends on who is buying each share as to their current worth, rather than their actual worth being the overriding factor (in which case they would be about equal).

The minute detail is as follows though:

The company has two tickers, MEDG and MEDU. This is for historical reasons because though AIM listed, Medgenics was incorporated in the US.

MEDG shares are restricted (which only really affects US buyers). This does not affect my UK rights to buy and sell the shares on AIM which I do as any other share, though I cannot get the shares certificated with TDW as a result and they have an online S marking. MEDG restricted shareholders can become unrestricted if the shareholder is not an affiliate of the Company and has held his/her Common Shares for at least one year.

MEDU shares were introduced to improve liquidity etc and to have unrestricted shares. More and more shares are becoming unrestricted and trading in Medgenics is expected to become much easier as a result. The MEDU ticker was set up in November 2008.

The significant majority of shares remain as MEDG at present though.

More and more shares should become unrestricted over time.

[tez123] 06/6/2010 12:50

Hi Kan,

Could you be kind enough to explain the difference between MEDG and MEDU shares.

TIA

Tez

[sicilian_kan] 26/5/2010 22:22

An open question. Are there any watchers out here, or am I bar one or two who have posted, on my own here?

Also, why do people think it is that Medgenics hasn't caught the market by fire yet. MEDU from 4.25p to 10.5p in a time of market decline, inc top of the leaderboard today is spectacular, but in terms of posts, nothing.

Yet other shares with far less merit have hoards of followers.

Any views?

[sicilian_kan] 26/5/2010 16:52

Medgenics (MEDU ticker) was No 1 on the ADVFN leaderboard today as best performing share.

[sicilian_kan] 26/5/2010 16:49

MEDU has risen to 10.5p mid today!

MEDG is just 6.25p

Am lucky to have had equal quantities of both, but may sell my (now much larger) MEDU holding and put into MEDG tomorrow if the difference between the two remains.

[sicilian_kan] 26/5/2010 07:14

Excellent news. Funding for second trial phase now complete. Same price as last funding round, so no drop. Patient recruitment has started. And Eugene Bauer, the Chairman buys over £100k.

[sicilian_kan] 24/5/2010 19:59

MEDU is having a cracking run and hit 8p today from 4p recently. I'd expect MEDG to catch up fairly soon as it has remained fairly constant at 6p.

[sicilian_kan] 20/5/2010 20:35

Interesting turn around in the last few days. MEDU is now 6.5p mid to MEDG's 6p. Only recently MEDU was 4.25p mid to MEDG's 6p.

Offers some great trading opportunities. I bought MEDU in April for 4.3p, now sellable at 6p I'd guess. Anyhow, the MEDU chart is looking quite strong, hopefully, the MEDG chart will follow it up too.

[sicilian_kan] 17/5/2010 08:23

This is surely a sign of progress. From SVS Securities to Nomura:

For release: 17 May 2010

Medgenics, Inc.
("Medgenics" or the "Company")

Appointment of Nomura-Code as Joint-Broker

Medgenics (LSE: MEDG, MEDU), the company that is developing a novel approach to the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, is proud to announce today the appointment of Nomura Code Securities as joint-broker to the Company with SVS Securities plc with immediate effect.

Commenting on the new appointment Dr. Andrew Pearlman, CEO of Medgenics said: "We are delighted by this new appointment and believe that the combination of Nomura Code Securities, with acknowledged expertise in the life sciences space and its reputation amongst institutional investors, and SVS Securities plc, with its small cap investor expertise, greatly strengthens Medgenics broking team to support the Company going forward"

[sicilian_kan] 14/5/2010 08:25

I got some more over there for 4.3p. It was a bargain and am not surprised they converged at some point, particularly as the final results came out last week. Haven't posted them here as they were too long and my laptop was in for repairs, but here are some new bits:

1) Attractive deals to take place in the next 12-24 months, in early payments:

"This demonstration of the Biopump as a platform technology helped convince our first pharmaceutical partner, a market leader in the field of haemophilia, to pursue with us a new application of the Biopump: to produce blood clotting Factor VIII, which if successful, could revolutionize the treatment of haemophilia. This first deal validated the commercial appeal of the Biopump
value proposition, the strength of the Biopump science, brought needed funds to
our operations and strengthened our ongoing efforts to raise equity funding.
This first commercial agreement has also spurred a substantial increase in commercial interest in the Biopump platform technology, as we found at the BioEurope conference in November 2009, and continuing in 2010. For Medgenics' more advanced pipeline applications, EPODURE in Phase I/II clinical trials in
anaemia, and INFRADURE in preclinical stage, Medgenics will seek during the coming 12-24 months to reach attractive terms with partners along the lines of recent deals for protein therapies, involving milestones for preclinical and early stage clinical applications".

"Meanwhile, we are continuing early stage development of a Factor VIII Biopump, with our commercial partner. The haemophilia (Factor VIII) Biopump deal structure potentially provides a model for new applications more generally, including a funding mechanism for proving feasibility of a new Biopump application before commencement of licensing negotiations. Following on this model, Medgenics is exploring opportunities for further commercial interest in new applications using the Biopump platform to provide superior delivery and treatment over existing protein therapies."

"These advances have brought Medgenics to what we believe is a new chapter: the pre-revenue commercialization stage, where the Company can now focus major attention on advancing partnering activities towards deals with bio/pharmaceutical or other therapeutic partners for Biopumps producing various proteins and clinical applications and with manufacturing partners to set up Biopump processing centres and produce Biopumps."

2) Patient recruitment has started for the extended EPODURE Phase I/II trial.

We have now obtained approval to extend our EPODURE Phase I/II trial to an
additional major teaching hospital in Israel's largest city, the Tel Aviv
Sourasky Medical Center, to continue with the higher dose treatments -
implementing an important step in our plan made possible by the recent and
ongoing fundraising, and have already commenced patient recruitment.

3) Company preparing for scale up to commercialisation.

"In addition to developing new protein applications of the Biopump, the Company has advanced, and continues to advance, its planning for practical scale-up and commercial implementation of its Biopump treatment technology. This includes designing automated Biopump processing technology utilizing low cost single-use sealed cassettes intended for use in regional or local Biopump processing centres capable of producing and storing Biopumps for hundreds or eventhousands
of patients per year, in a cost-effective manner."

4) Newly found partnering opportunities for more deals.

"As the Biopump processing centre model evolves, an additional concept for partnering has emerged and garnered interest from potential partners: the establishment and operation of regional or even local Biopump processing centres. This model can offer pharmaceutical partners the advantages of Biopump therapy in their market applications, building on their existing infrastructure for selling injected therapeutics, while sparing them the need to establish their own Biopump processing centres."

5) Primary and secondary objectives met in majority of patients at lowest dose, despite not being expected to be sufficient.

"The data generated in the seven patients in the trial to date is highly encouraging, with all EPODURE Biopumps producing EPO to an acceptable level before administration and, once implanted in the patients, delivering active EPO into the patients for months, with no material adverse effects, and resulting in haemoglobin elevation and maintenance of an unprecedented 6-12 months from a single administration of EPODURE Biopumps. The primary endpoint for successful treatment was the sustained elevation of haemoglobin level for up to 6 months in each patient following EPODURE treatment compared to the levels projected for the same period without EPO injections, and without EPODURE treatment. A secondary objective was, for appropriate dose for a given patient, to maintain haemoglobin within the target range for these patients for a sustained period. Both these were attained in most patients, even at the lowest dose of only 20IU/kg/day, with sustained levels of haemoglobin over 6-12 months. In one formerly EPO-dependent patient, whom we have been following over 18 months, the haemoglobin levels have remained in the target range for all of that time, which is a considerable achievement for the technology, both for EPODURE itself and for the Biopump technology platform more generally."

"As the low dose was designed to be equivalent to the low end of the FDA approved EPO dosing range (3 weekly injections of 50 IU/kg), which is not normally sufficient to raise haemoglobin to target levels in most patients in routine use, we were not expecting our low dose EPODURE to be sufficient for most patients. Thus, we were very pleased to note that, nonetheless, most patients responded even at this low dose. In accordance with the study protocol, in those cases where the haemoglobin levels remained below target range, those patients exited the study to receive supplementary injections of EPO. In clinical practice, additional Biopumps would be administered to raise the haemoglobin level, but the protocol of the current trial does not allow for
that."

6) Hemophilia data expected H2 2010 pursuant to the agreement with the tier one international pharmaceutical company.

"We anticipate having early in vitro data during the second half of this year."

7) Hemophilia $3m option extension followed by 2011 full licensing deal could happen (assuming the in vitro tests are good), thus generating cash flows.

"Additional payments totalling $3 million are payable upon Medgenics meeting certain technical milestones and upon the partner's exercise of an option to extend the exclusivity through an additional period to negotiate terms to commercialize the Biopump technology for Factor VIII. We anticipate having early in vitro data during the second half of this year, which could lead to the first licensing deal for the technology in 2011."

8) Partnering talks have expanded with additional companies showing interest. Updates will be given in due course.

"The Company's active discussions with potential strategic partners have expanded with additional companies expressing interest in one or more therapeutic applications. Furthermore, as the Company has developed its model for Biopump regional processing centres, this model has sparked new interest in the Biopump as a technology platform, particularly in potential partners with expertise in manufacturing and in medical devices. Further updates on these discussions will be given in due course."

9) Most of the 2010 program funds are non-dilutive.

"Of the funds required for the 2010 program, a total of about $4m is expected in non-dilutive funding from a combination of the Factor VIII Biopump deal (of which $1.4m has already been received in 2010) and in funding from the Office of the Chief Scientist in Israel."

My understanding is a further $2m will be required, but I think this should take us to the option agreement where $3m will be triggered during the option exercising talks. So I hope that this would be the last $2m required.

10) Further details of the hemophilia deal are provided.

"Under the terms of the Agreement, the Company will receive up to $4.1 million to work exclusively with the healthcare company for one year to develop a Biopump to test the feasibility of continuous production and delivery of this clotting protein. The amount of $4.1 million will include the following:
· $1.5 million to work exclusively with the healthcare company (Standstill
Payment)
· $2.6 million as development funding
Additional payments totaling $3 million are payable upon the Company's meeting certain milestones ($0.5 million) and upon the healthcare company's exercise of an option to extend the exclusivity through an additional period to negotiate terms to commercialize the Biopump technology for FVIII ($2.5 million).

If the two parties choose not to proceed to a full commercial agreement, the Company will receive all rights to the jointly developed intellectual property and will pay royalties to the healthcare company on any future proceeds arising from such intellectual property up to a maximum of ten times the total funds paid by the healthcare company."

11) Details of the payments payable to Yissum from whom they got patents are provided.

$150,000 will soon be due as Medgenics will have had $12m invested in the company soon. 5% royalties are due, however "The total aggregate payment of royalties and Sub-license fees by the Company to Yissum shall not exceed $10,000,000."

If the Biopump takes off, paying royalties of such a sum will be a drop in the ocean, imho.

12) Similar good terms are reached with the Office of the Chief Scientist, who have been part funding Medgenics:

"Under agreements with the Office of the Chief Scientist in Israel regarding research and development projects, the subsidiary is committed to pay royalties to the Office of the Chief Scientist at rates between 3.5% and 5% of the income resulting from this research and development, at an amount not to exceed the amount of the grants received by the subsidiary as participation in the research and development program, plus interest at LIBOR. The obligation to pay these royalties is contingent on actual income and in the absence of such income no payment is required. As of December 31, 2009 the aggregate contingent liability amounted to approximately $3.7 million."

T

[crimeprotection1] 12/5/2010 12:21

Suppose the mm's have finally realised that MEDU has been nowhere near MEDG for sometime, wish I'd bought now at 4p.

[andrbea] 12/5/2010 12:10

medu up 26%

medg: flat

why the discrepancy?

[sicilian_kan] 28/4/2010 22:52

Another great RNS.

Now, one of Israels largest and most prestigious medical centres has taken on the trial too.

All patients previously treated were responders and met the minimum EPO recommended dose, with most in the target range, even on the low dose.

Now the best patient has gone 18 months without injections.

Now the dose can will be doubled or tripled in the newest trial.

Patients for the new trial will be expected to be dosed in the next few weeks.

[sicilian_kan] 28/4/2010 22:44

RNS Number : 8434K
Medgenics Inc
27 April 2010

Medgenics, Inc.

('Medgenics' or the 'Company')

MEDGENICS GRANTED APPROVAL FOR EXTENSION OF ANAEMIA TRIAL TO MAJOR NEW MEDICAL CENTRE

Misgav, Israel and London, UK -27 April 2010 - Medgenics (AIM: MEDG, MEDU) is pleased to announce that it has received approval from Israel's Ministry of Health (MOH) to proceed with higher dose groups in the phase I-II clinical trial of its novel sustained anaemia treatment, EPODURE, at an additional new site, the Tel Aviv Sourasky Medical Centre, one of the largest teaching hospitals in Israel. Following the first closing of the Company's interim fund raising, as announced on 5 March 2010, patient recruitment will commence shortly for the new centre, with the first patients expected to receive their Biopumps within a few weeks of enrollment. Medgenics has already reported sustained anaemia treatment of unprecedented duration from a single treatment in most patients in the low dose group in this study and hopes to prove the efficacy of EPODURE further in this higher dose study.

The new higher dose study groups aim to assess the safety and efficacy of EPODURE at increased, controlled dose ranges, noting that among the seven patients already treated in the Company's clinical trial to date, no signs of adverse reactions have been noted, and all patients tolerated all study procedures very well. From the clinical efficacy perspective, the six patients in the low dose group received sufficient EPODURE Biopumps to provide the lowest recommended dosage of erythropoietin (EPO) on a continuous basis: 20 EPO units or IU/kg/day. All patients showed delivery of active EPO, with most showing sustained elevation of haemoglobin levels (the primary endpoint) in the target range of 10-12 g/dl for 6-12 months, without receiving any further injections of EPO. One of these patients maintained haemaglobin levels in the normal range for more than 18 months without any EPO injections. The seventh patient has already received the midrange dose of 40 IU/kg/day and also maintained haemoglobin levels for six months without adverse events.

Medgenics' unique platform approach to providing safer, more effective and lower cost protein therapy uses the patient's own tissue to act as a biological pump or "Biopump" to continuously produce their own therapeutic proteins. Needle biopsies are taken from the lower layer of the patient's skin under local anesthetic, and processed during 10-14 days to become tissue biofactories producing the required protein. The requisite number of Biopumps are then injected under the patient's skin to provide sustained protein production and delivery for many months.

In the next dose group of the study, sufficient EPODURE Biopumps will be administered to each patient to provide 40 IU/kg/per day or 60 IU/kg per day, which may enable more of the patients to maintain haemaglobin in the target range for extended periods of time. Dr. Doron Schwartz, Head of the Nephrology department at the centre, as the new Principal Investigator, has already recruited the active support of his department for the study.

Commenting on the approval, Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, said:

"The extension of our study to one of Israel's largest and most prestigious medical centres is an important milestone for EPODURE and the Medgenics Biopump platform technology for the continuous production and delivery of therapeutic proteins in the patient. This important step has been made possible by the encouraging results achieved to date, together with the first closing of our current round of fundraising, and we look forward to moving ahead on this and other steps in our program as additional funds are raised in the coming months.

The enthusiastic involvement of Dr. Schwartz and his department is particularly welcomed as we proceed towards completion of this trial in a timely manner, and we hope that we will now have more rapid patient recruitment than we have had to date.

Given the very encouraging results at low dose levels, we are looking much forward to seeing the results from the higher doses in this trial."

[sicilian_kan] 25/4/2010 22:20

Agreed. At present MEDU is the better buy. It does trade because I have bought some a few weeks ago. MEDU is cheaper and unrestricted. I think MEDG is doing better as it has more shares on its ticker and it is closer in name to the name of the company. But if there is a takeover, far better to buy MEDU at around 4p (I got in at 4.3p) than MEDG 6-7p. Your shares will be 3:2 in your favour then.

[crimeprotection1] 25/4/2010 21:22

Surely the MEDU price is the better price for would be buyers, it doesn't trade whatsoever but yet has mirrored all the spikes of MEDG??

[sicilian_kan] 25/4/2010 18:24

Mention on Red Hot Penny Shares today:



"The biotech and pharmaceutical "strongholds" that could see you make huge profits... whatever the economy does next.

In 2010, the biotech and pharmaceutical sector will be the savvy investors' niche.

Recession has hit other industries where it hurts...but disease and illness aren't governed by the same rules as the economy...

The human race seems to be contracting more viruses, infections and diseases than ever before...and it's the tiny small cap biotechnology and pharmaceutical companies - not the industry's heavyweights, like AstraZeneca and GlaxoSmithKline - that are delivering the answers.

The investor that knows where to look - and when to invest - could make serious, serious money from under-valued biotech and pharma penny shares over the next year.

How one breakthrough could see you pocket fast triple figure gains...

Just check out these biotech and pharma success stories from the 3 months between August and October:

* Phytopharm (ticker: PYM) shot up a staggering 278%... after news of their new Parkinson's drug was released
* Medgenics (ticker: MEDG) shares soared by 78%... when they signed a new deal for their revolutionary product to treat haemophilia
* Verona Pharma (ticker: VRP) rocketed by 117 %... thanks to positive trials of their asthma drug RPL554

..."